Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 125 results for epilepsies

  1. Does the addition of THC to CBD have an effect on seizure frequency, brain structure and neuropsychological performance when compared with both CBD alone and placebo in epileptic disorders in children, young people and adults?

    recommendationsThe only cannabis-based medicinal product available for the treatment of epilepsy is epidyolex, which is licensed...

  2. Transcranial magnetic stimulation for auditory hallucinations (HTG555)

    Evidence-based recommendations on transcranial magnetic stimulation for auditory hallucinations. This involves stimulating the brain with pulses of electromagnetic energy.

  3. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.

  4. Transcranial magnetic stimulation for treating and preventing migraine (HTG330)

    Evidence-based recommendations on transcranial magnetic stimulation for treating and preventing migraine. This involves placing a handheld device on the scalp to deliver magnetic pulses to the head.

  5. Physical health of people in prisons (QS156)

    This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.

  6. Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]

    Awaiting development Reference number: GID-TA10519 Expected publication date: TBC

  7. Brain tumours (primary) and brain metastases in over 16s (NG99)

    This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.

  8. Sustainability

    NICE is committed to supporting the national agenda for achieving a sustainable health and care system.

  9. Spasticity in under 19s: management (CG145)

    This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.

  10. Antiseizure medication for repeated or cluster seizures: What antiseizure medications (monotherapy or add-on) are effective in the treatment of repeated or cluster seizures?

    therapies. Source guidance details Comes from guidance Epilepsies in children, young people and adults Number NG217 Date

  11. Antisocial behaviour and conduct disorders in children and young people (QS59)

    This quality standard covers recognising and managing antisocial behaviour and conduct disorders in children and young people. It describes high-quality care in priority areas for improvement.

  12. Antenatal and postnatal mental health (QS115)

    This quality standard covers recognising, assessing and treating mental health problems in women planning, during or after pregnancy (up to a year after childbirth). It also covers the organisation of mental health services for women during and after pregnancy. It describes high-quality care in priority areas for improvement.

  13. Autism spectrum disorder in adults: diagnosis and management (CG142)

    This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.